Related Experiment Video
Updated: Aug 14, 2026
11:02
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
Systemic chemotherapy in inoperable or metastatic bladder cancer
A Bamias1, I Tiliakos, M-D Karali
1Department of Clinical Therapeutics, Medical School, University of Athens, Greece. abamias@med.uoa.gr
Summary
Advanced urothelial cancer treatment has improved with novel chemotherapy agents like gemcitabine and taxanes. New strategies offer better survival chances, especially for specific patient groups and those without metastases.
Area of Science:
- Oncology
- Urothelial Carcinomas
- Medical Treatments
Background:
- Urothelial cancer management is challenging, especially for recurrent, metastatic, or unresectable cases.
- Systemic chemotherapy improves survival but long-term outcomes are infrequent.
- Novel agents like gemcitabine and taxanes have enhanced treatment efficacy.
Purpose of the Study:
- To review current and emerging treatment strategies for advanced urothelial cancer.
- To discuss the efficacy and toxicity profiles of different chemotherapy regimens.
- To explore treatment considerations for specific patient populations and the potential of targeted therapies.
Main Methods:
- Review of recent advancements in systemic chemotherapy for urothelial cancer.
- Analysis of novel chemotherapeutic agents and combination therapies.
- Evaluation of treatment approaches for elderly patients, those with renal impairment, or comorbidities.
- Consideration of retrospective analyses for patient stratification.
- Exploration of targeted therapies in advanced urothelial cancer.
Main Results:
- Novel agents (gemcitabine, taxanes) and modified regimens (MVAC, gemcitabine-cisplatin) show improved efficacy and/or toxicity profiles.
- Alternative chemotherapy (carboplatin, taxanes) benefits patients unfit for cisplatin-based regimens.
- Retrospective analyses identify prognostic groups requiring tailored therapeutic approaches.
- Modern chemotherapy offers long-term survival potential, particularly for patients without visceral metastases.
- Biological agents are being investigated for combination with chemotherapy in advanced urothelial cancer.
Conclusions:
- Modern chemotherapy, including novel agents and tailored regimens, has improved outcomes for advanced urothelial cancer.
- Individualized treatment strategies are crucial, especially for specific patient subgroups.
- Targeted therapies hold promise for future treatment combinations in advanced urothelial cancer, pending further evaluation.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:25Urinary Tract Calculi VI: Surgical Management
Procedures for Kidney StonesMedical intervention is necessary when kidney stones or renal calculi are too large to pass spontaneously (typically greater than 5 millimeters) when stones are accompanied by symptomatic infection (such as fever or pyelonephritis), when they impair kidney function, or when they cause persistent symptoms like severe pain, nausea, or urinary retention. Additionally, patients with only one kidney or those who cannot be treated with medical management also require...